Risk factors for cerebral palsy in neonates due to placental abruption

Kiyotake Ichizuka1,2, Satoshi Toyokawa1,3, Tsuyomu Ikenoue1,4, Shoji Satoh1,5, Junichi Hasegawa1,6, Tomoaki Ikeda1,7, Nanako Tamiya1,8, Akihito Nakai1,9, Keiya Fujimori1,10, Tsugio Maeda1,11, Naohiro Kanayama1,12, Hideaki Masuzaki1,13, Mitsutoshi Iwashita1,14, Hideaki Suzuki1 and Satoru Takeda1,15

1Department of the Japan Obstetric Compensation System for Cerebral Palsy in Public Interest Incorporated Foundation, Japan Council for Quality Health Care, Tokyo, Japan
2Department of Obstetrics and Gynecology, Showa University Northern Yokohama Hospital, Yokohama, Japan
3Department of Public Health, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
4Department of Obstetrics and Gynecology, Faculty of Medicine, Miyazaki University, Miyazaki, Japan
5Department of Obstetrics, Oita Prefectural Hospital, Oita, Japan
6Department of Obstetrics and Gynecology, Saint Marianna University School of Medicine, Kawasaki, Japan
7Department of Obstetrics and Gynecology, Meie University, Tsu, Japan
8Department of Health Services Research, Faculty of Medicine, Tsukuba University, Tsukuba, Japan
9Department of Obstetrics and Gynecology, Nippon Medical University, Tokyo, Japan
10Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
11Maeda Obstetrics and Gynecology Clinic, Yaizu, Japan
12Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
13Department of Obstetrics and Gynecology, Nagasaki University, Nagasaki, Japan
14Kugayama Hospital, Tokyo, Japan
15Department of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan

Abstract

**Aim:** This study aimed to identify risk factors for the onset of cerebral palsy (CP) in neonates due to placental abruption and investigate their characteristics.

**Methods:** A retrospective case–control study was conducted using a nationwide registry from Japan. The study population included pregnant women (n = 122) who delivered an infant with CP between 2009 and 2015, where placental abruption was identified as the single cause of CP. The control group consisted of pregnant women with placental abruption, who delivered an infant without CP and were managed from 2013 to 2014. They were randomly identified from the prenatal database of the Japan Society of Obstetrics and Gynecology (JSOG-DB; n = 1214). Risk factors were investigated using multivariate analysis.

**Results:** Alcohol consumption (3.38, 2.01–5.68) (odds ratio, 95% confidence interval), smoking during pregnancy (3.50, 1.32–9.25), number of deliveries (1.28, 1.05–1.56), polyhydramnios (5.60, 1.37–22.6), oral administration of ritodrine hydrochloride (2.09, 1.22–3.57) and hypertensive disorders in pregnancy (2.25, 1.27–4.07) were significant risk factors. In contrast, intravenous administration of oxytocin (odds ratio, 95% confidence interval: 0.22, 0.09–0.58) and magnesium sulfate (0.122, 0.02–0.89) attenuated risk.

**Conclusion:** Alcohol consumption, smoking during pregnancy, number of deliveries, polyhydramnios, oral administration of ritodrine hydrochloride and hypertensive disorders in pregnancy were identified as risk factors for CP following placental abruption. Regarding alcohol consumption and smoking during

**Received:** February 24 2020.
**Accepted:** August 2 2020.

Correspondence: Dr Kiyotake Ichizuka, Department of Obstetrics and Gynecology, Showa University Northern Yokohama Hospital, 35-1 Chigasaki Chuo Tsuzuki-ku Yokohama, Kanagawa 224-8503, Japan. Email: ichizuka@med.showa-u.ac.jp

© 2020 The Authors. Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
pregnancy, the results suggest the importance of educational activities targeting pregnant women to increase their awareness of placental abruption.

**Key words:** alcohol consumption, cerebral palsy, placental abruption, risk factors, smoking.

**Introduction**

Placental abruption is an uncommon condition where the placenta detaches from the inner wall of the uterus before birth. The reported frequency of placental abruption is approximately 5.9 in 1000 deliveries in singleton pregnancies and 12.2 in 1000 in twin pregnancies. The rate of perinatal mortality in pregnancies complicated by placental abruption is more than 10 times higher than the overall perinatal mortality rate.\(^1\)\(^-\)\(^3\) In Japan, it has been reported that the adjusted relative risk of cerebral palsy (CP) due to placental abruption is 20.891 (95% confidence interval [CI]: 11.817–36.934).\(^4\) Hypertensive disorders in pregnancy, a history of placental abruption, intra-amniotic infection, preterm labor, preterm rupture of membranes, trauma, smoking and alcohol consumption are known risk factors for placental abruption.\(^1\)\(^,\)\(^2\)\(^,\)\(^5\) Yamada et al.\(^6\) reported that placental abruption was the causative factor in 28 (26%) of 107 infants with CP, making it the single leading causative factor. However, there have been no studies on prepartum risk factors in cases of CP due to placental abruption. If other risk factors for placental abruption can be addressed, the actual incidence of CP due to placental abruption may decrease. This study aimed to identify risk factors for the onset of CP due to placental abruption and investigate their characteristics.

**Methods**

A retrospective case–control study was conducted using the perinatal database of the Japan Society of Obstetrics and Gynecology (JSOG-DB), which is the largest registry in Japan. Obstetric clinical characteristics and obstetric risk factors were compared between the CP cases (\(n = 122\)) and control cases (\(n = 1214\)).

The CP cases comprised infants with CP for whom compensation was approved in a review by the operating organization of the Japan Obstetric Compensation System for Cerebral Palsy (JOCSC). The JOCSC provides prompt no-fault compensation for children diagnosed with severe CP caused by trauma during labor and delivery, as well as for their respective families. Compensation cases are reviewed by a committee consisting of obstetricians, pediatricians, midwives and lawyers, according to the rules of the Operating Organization of the JOCSC. After being deemed as eligible to receive compensation by this review committee, the causes of CP are analyzed individually by the Causal Analysis Committee, which consists of obstetricians, pediatricians, midwives and lawyers.

Cases involving pregnant women who delivered an infant with CP, in which placental abruption was identified as the single cause of CP, were eligible for inclusion in the present study (\(n = 122\)). All infants were born between January 2009 and December 2015 and had a birth weight of \(\geq 2000\) g, gestational age of \(\geq 33\) weeks and severe disability due to CP (unassociated with congenital causes or factors that occurred during the neonatal period or later), with a disability certified as first- or second-degree severity according to the definitions in the Act for the Welfare of Persons with Physical Disabilities (https://www.dinf.ne.jp/doc/english/resource/z00009/z0000901.html).

The control participants’ data were extracted from the perinatal database of the JSOG-DB, the largest registry in Japan established in 1974. The JSOG-DB accumulates data annually from 192 secondary and tertiary care centers of the Perinatal Research Network in Japan, recording approximately 24.9% of total births and approximately 51.6% of perinatal deaths. It collects data on each pregnant woman through an offline clinical database system using a common format, which are then stored with strict quality control of the information.\(^7\) It is available to clinical researchers in Japan and has been used in similar studies.\(^4\)\(^,\)\(^6\)\(^,\)\(^8\)\(^,\)\(^9\) In this study, the control group, included pregnant women with placental abruption who delivered an infant without CP between 2013 and 2014. Control participants (\(n = 1214\)) were randomly retrieved from the JSOG-DB. The data of all participants (\(n = 1336\)) are shown in Figure 1.

The statistical power asymptotically increases by the number of matching controls; 10 controls per each CP case are sufficient to obtain converged statistical power. We avoided using all control candidates from
the database because erroneous data inputted by mistake might be included in the analysis dataset. Fortunately, the results using a 1:10 matching control ratio and the entire control cohort were identical.

The explanatory variables in this study were age, height, prepregnancy body weight, bodyweight increase during pregnancy, alcohol consumption during pregnancy, smoking before and during pregnancy, multiparity, diabetes mellitus, thyroid disease, uterine fibroids, assisted reproductive technology (ART), oligohydramnios, polyhydramnios, oral administration of ritodrine hydrochloride, intravenous administration of ritodrine hydrochloride, intravenous administration of magnesium sulfate, intravenous administration of oxytocin, oral administration of aspirin, intramuscular injection of betamethasone, preterm rupture of membranes, intrauterine infection, preterm labor, hypertensive disorders in pregnancy and gestational age.

### Statistical analysis

Relationships among clinical variables were evaluated using univariate and multivariate logistic regression analyses with CP as the independent variable. Results are expressed as odds ratios (ORs) and 95% CIs. Univariate and multivariate analyses were performed using explanatory variables to calculate the crude odds ratios (cORs) and adjusted odds ratios (aORs). The significant explanatory variables that were identified in univariate analysis and variables considered to be clinically important, such as maternal age, height, bodyweight before pregnancy, body weight increase during pregnancy and birth weight, were entered into a multivariate model. Two-sided \( P \) values <0.05 were considered statistically significant. All analyses were conducted using STATA version 13.0 (STATA Corporation).

### Definitions

**Cerebral palsy**

Cerebral palsy was defined as a disturbance of the motor function or posture of infants that is permanent or variable. The disorder is based on a nonprogressive cerebral lesion that may develop at any time between conception and the neonatal period (within 4 weeks after birth). However, this definition excludes motor retardation, which is either transient or normalizes in the future.

**Placental abruption**

In this study, placental abruption was diagnosed according to the judgment of the attending physician based on the clinical course, such as abdominal pain with bleeding, abnormal fetal heart pattern on cardiotocography, the existence of retroplacental}

### Table 1 Demographics of the cerebral palsy and control groups

|                | Control \( n = 1214 \) | Case \( n = 122 \) |
|----------------|------------------------|-------------------|
| **Mean**       | **SD**                 | **Min.**          | **Max.**          |
| Age            | 32.5                   | 5.18              | 16                | 48                |
| Height         | 158.1                  | 5.62              | 136.2             | 177               |
| Body weight before pregnancy | 53.1         | 9                 | 35                | 102               |
| Body weight before delivery   | 62               | 8.8               | 40.1              | 99.1              |
| BMI            | 21.2                   | 3.4               | 14.8              | 40                |
| Body weight gaining       | 8.87      | 4.42              | −14               | 35                |
| Birth weight    | 2682.2                 | 401.3             | 2002              | 4192              |
| Apgar score 1 min | 6.7          | 2.3               | 0                 | 10                |
| Apgar score 5 min | 8.2          | 1.6               | 0                 | 10                |
| Umbilical artery blood pH | 7.221      | 0.14              | 6.512             | 7.55              |
|                | **Mean**               | **SD**            | **Min.**          | **Max.**          |
|                |                        |                   |                   |                   |

© 2020 The Authors. *Journal of Obstetrics and Gynaecology Research* published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.
hematoma on ultrasonography and other clinical findings.

**Ethics**

The study protocol was approved by the institutional review board of the JOCSC (approval number: 26–1). Written informed consent was not obtained from the patients, as this was a retrospective study. However, patients were provided with a supplemental file that contained the announcement of the implementation of a ‘case-control study for cerebral palsy and prevention of its recurrence’. Although the analysis was retrospective, the anonymized data of the CP patients, retrieved from the JOCSC-DB, and those of the control cohort, retrieved from the JSOG-DB, had been collected in a normal clinical setting, ensuring that patient confidentiality was protected. All the patient data were anonymized and de-identified before the analysis. No personal information was necessary for the present study.

This study does not violate the policies and procedures of the journal and conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo, 2004).

| Table 2 | Assessment of obstetric factors in the cerebral palsy and control groups |
|---------|---------------------------------------------------------------|
|         | Case | Control |
|         | \( n = 122 \) | \( n = 1214 \) |
| Alcohol consumption during pregnancy | 29 | 23.8% | 97 | 8.0% |
| Smoking before pregnancy | 23 | 18.9% | 141 | 11.6% |
| Smoking during pregnancy | 13 | 10.7% | 44 | 3.6% |
| Diabetes mellitus | 1 | 0.8% | 67 | 5.5% |
| Gestational diabetes mellitus | 1 | 0.8% | 60 | 4.9% |
| Thyroid disease | 1 | 0.8% | 32 | 2.6% |
| Uterine fibroid | 6 | 4.9% | 63 | 5.2% |
| Number of birth 1 | 43 | 35.2% | 408 | 33.6% |
| Number of births 2 | 26 | 21.3% | 145 | 11.9% |
| Number of births 3 | 5 | 4.1% | 36 | 4.0% |
| Number of births 4 | 5 | 4.1% | 13 | 1.1% |
| Number of births 5 | 0 | 0.0% | 3 | 0.2% |
| Number of births 6 | 0 | 0.0% | 1 | 0.1% |
| Number of births 7 | 0 | 0.0% | 1 | 0.1% |
| Multiparity | 79 | 64.8% | 607 | 50.0% |
| Assisted reproductive technology (ART) | 1 | 0.8% | 66 | 5.4% |
| Polyhydramnios | 3 | 2.5% | 9 | 0.7% |
| Oligohydramnios | 3 | 2.5% | 27 | 2.2% |
| Oral administration of ritodrine hydrochloride | 49 | 40.2% | 241 | 19.9% |
| Intravenous administration of ritodrine hydrochloride | 13 | 10.7% | 195 | 16.1% |
| Intravenous administration of magnesium sulfate | 1 | 0.8% | 77 | 6.3% |
| Oral administration of aspirin | 1 | 0.8% | 19 | 1.6% |
| Intramuscular injection of betamethasone | 0 | 0.0% | 16 | 1.3% |
| Preterm rupture of membranes | 17 | 13.9% | 147 | 12.1% |
| Intravenous administration of oxytocin | 5 | 4.1% | 194 | 16.0% |
| Intraterine infection | 12 | 9.8% | 105 | 8.6% |
| Preterm labor | 47 | 38.5% | 310 | 25.5% |
| Hypertensive disorder in pregnancy | 21 | 17.2% | 124 | 10.2% |
| Gestational age (week) | | | | |
| 33 | 4 | 3.3% | 30 | 2.5% |
| 34 | 7 | 5.7% | 83 | 6.8% |
| 35 | 16 | 13.1% | 135 | 11.1% |
| 36 | 15 | 12.3% | 171 | 14.1% |
| 37 | 28 | 23.0% | 206 | 17.0% |
| 38 | 26 | 21.3% | 235 | 19.4% |
| 39 | 16 | 13.1% | 192 | 15.8% |
| 40 | 7 | 5.7% | 125 | 10.3% |
| 41 | 3 | 2.5% | 37 | 3.0% |
| 42 | 0 | 0.0% | 1 | 0.1% |

© 2020 The Authors. *Journal of Obstetrics and Gynaecology Research* published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.
Results

Data for 122 patients with CP were retrieved from the JOCSC-DB, and data for 1214 controls were randomly retrieved from the JSOG-DB. The demographic variables are shown in Table 1.

The explanatory variables that may be associated with risk factors for placental abruption in the CP and Table 3  Univariate analysis of obstetric factors identified in the cerebral palsy and control groups

| Univariate analysis                  | cORs       | 95%CIs               | P-value |
|-------------------------------------|------------|----------------------|---------|
| Alcohol consumption during pregnancy| 3.591      | 2.254–5.720          | <0.001  |
| Smoking before pregnancy            | 1.768      | 1.087–2.876          | 0.022   |
| Smoking during pregnancy            | 3.171      | 1.657–6.069          | <0.001  |
| Diabetes mellitus                   | 0.141      | 0.019–1.028          | 0.053   |
| Gestational diabetes mellitus       | 0.159      | 0.022–1.157          | 0.069   |
| Thyroid disease                     | 0.305      | 0.041–2.254          | 0.245   |
| Uterine fibroid                     | 0.945      | 0.400–2.231          | 0.897   |
| Number of births (increased every once) | 1.365      | 1.155–1.613          | <0.001  |
| Multiparity                         | 1.837      | 1.246–2.708          | 0.002   |
| Assisted reproductive technology (ART) | 0.144      | 0.020–1.045          | 0.055   |
| Polyhydramnios                      | 3.375      | 0.902–12.637         | 0.071   |
| Oligohydramnios                     | 1.108      | 0.331–3.708          | 0.867   |
| Oral administration of ritodrine hydrochloride | 2.710      | 1.838–3.996          | <0.001  |
| Intravenous administration of ritodrine hydrochloride | 0.623      | 0.347–1.130          | 0.119   |
| Intravenous administration of oxytocin | 0.225      | 0.091–0.557          | 0.001   |
| Intravenous administration of magnesium sulfate | 0.122      | 0.017–0.885          | 0.004   |
| Oral administration of aspirin      | 0.520      | 0.069–1.917          | 0.525   |
| Intramuscular injection of betamethasone | 1.000      |                     |         |
| Preterm rupture of membranes        | 1.175      | 0.684–2.018          | 0.558   |
| Intrauterine infection              | 1.152      | 0.615–2.160          | 0.659   |
| Preterm labor                       | 1.827      | 1.241–2.690          | 0.002   |
| Hypertensive disorder in pregnancy  | 1.828      | 1.203–3.030          | 0.019   |
| Gestational age (increased every week) | 0.943      | 0.857–1.037          | 0.228   |

aOR, crude odds ratio; CIs, confidence intervals.

Table 4  Multivariate analysis of all variables

| Multivariate analysis               | aORs       | 95% CIs               | P-value |
|-------------------------------------|------------|----------------------|---------|
| Age                                 | 0.972      | 0.933–1.012          | 0.172   |
| Height                              | 0.984      | 0.947–1.023          | 0.426   |
| Body weight before pregnancy        | 1.011      | 0.986–1.036          | 0.396   |
| Body weight increase during pregnancy | 1.033      | 0.983–1.086          | 0.199   |
| Birth weight                        | 1.003      | 0.999–1.006          | 0.125   |
| Birth weight SD                     | 0.444      | 0.140–1.404          | 0.167   |
| Alcohol consumption during pregnancy | 3.383      | 2.013–5.865          | <0.001  |
| Smoking before pregnancy            | 1.481      | 0.350–1.542          | 0.415   |
| Smoking during pregnancy            | 3.495      | 1.321–9.250          | 0.012   |
| Multiparity                         | 1.284      | 1.059–1.558          | 0.011   |
| Polyhydramnios                      | 5.604      | 1.374–22.865         | 0.016   |
| Oligohydramnios                     | 1.188      | 0.320–4.413          | 0.797   |
| Oral administration of ritodrine hydrochloride | 2.093      | 1.226–3.573          | 0.007   |
| Intravenous administration of ritodrine hydrochloride | 0.509      | 0.256–1.012          | 0.054   |
| Intravenous administration of magnesium sulfate | 0.136      | 0.018–1.029          | 0.053   |
| Intravenous administration of oxytocin | 0.223      | 0.086–0.580          | 0.002   |
| Intrauterine infection              | 1.063      | 0.535–2.113          | 0.862   |
| Preterm labor                       | 1.562      | 0.879–2.777          | 0.128   |
| Hypertensive disorder in pregnancy  | 2.252      | 1.265–4.010          | 0.006   |
| Gestational age                     | 0.657      | 0.382–1.130          | 0.224   |

aOR, adjusted odds ratio; CI, confidence intervals.
control groups are shown in Table 2. A univariate analysis of the explanatory variables identified alcohol consumption (3.59, 2.25–5.72, <0.01) (cORs, 95% CIs, P-value), smoking before pregnancy (1.77, 1.09–2.88, 0.022), smoking during pregnancy (3.17, 1.66–6.07, <0.01), the number of births (the risk increasing with each additional delivery; 1.37, 1.16–1.61, <0.001), multiparity (1.84, 1.25–2.71, 0.002), oral administration of ritodrine hydrochloride (2.71, 1.84–4.00, <0.001), preterm labor (1.83, 1.24–2.69, 0.002) and hypertensive disorders in pregnancy (1.83, 1.20–3.03, 0.0019) as significant risk factors for CP. Among these, alcohol consumption during pregnancy showed the strongest association with CP. In contrast, the intravenous administration of magnesium sulfate (0.122, 0.02–0.89, 0.004) and the intravenous administration of oxytocin (0.23, 0.09–0.56, 0.001) significantly attenuated the risk of developing CP (Table 3).

In the multivariate analysis, alcohol consumption (3.38, 2.01–5.68, <0.001) (aORs, 95% CIs, P-value), smoking during pregnancy (3.50, 1.32–9.25, 0.012), multiparity (1.28, 1.05–1.56, 0.011), polyhydramnios (5.60, 1.37–22.6, 0.016), oral administration of ritodrine hydrochloride (2.09, 1.22–3.57, 0.007) and hypertensive disorders in pregnancy (2.25, 1.27–4.07, 0.006) were identified as significant independent risk factors. Intravenous administration of oxytocin significantly attenuated the risk of developing CP (0.22, 0.09–0.58, 0.002) (OR, 95% CI) (Table 4, Figure 2).

Discussion

Cerebral palsy, especially that originating in the intrapartum period, not only impacts the patient and parents but is also a significant medicolegal matter. In the last two decades, medicolegal claims arising from perinatal brain injury have continued growing. In Japan, obstetrics-related lawsuits filed between 2004 and 2008 accounted for approximately 10–15% of the overall total across all specialties. However, since the institution of this system, obstetrics-related lawsuits have started to fall to approximately 7% of the total. Nevertheless, CP remains the subject of lawsuits, and improving prevention is an important obstetrical issue. For that reason, it is necessary to investigate its cause and risk factors. Against this background, various studies have investigated the cause of CP and its risk factors. Previous research has identified placenta previa as one of the leading causes of CP.

In this study, we found that the umbilical cord blood pH was significantly lower after placenta abruption in the CP group than in the non-CP group. Moreover, we elucidated the risk factors for CP occurring during pregnancy following a placental abruption.

A study that analyzed the umbilical cord blood pH revealed acidemia (pH ≤7.0) in 114 of 168 (69.2%), neonates, with severe CP and in 42 of 42 (100%) fetuses with CP in cases involving placental abruption. According to a report by the JOCSC, more than half of all CP cases showed umbilical cord blood pH of less than 7.0, indicating that fetal acidemia is closely related to CP. Our cohort was also derived from the JOCSC database, which only includes CP due to causes related to pregnancy and delivery, excluding congenital malformations or postnatal causes. Another report found that a pH <7.0 was an essential criterion in defining the cause as intrapartum. Matsuda et al. reported that fetal bradycardia is the most important risk factor for CP among patients with a fetal heart-tracing pattern. Conversely, there are no reports on risk factors related to the onset of CP in patients with placental abruption. Alcohol drinking, smoking during pregnancy, multiparity, polyhydramnios and hypertensive disorders in pregnancy have previously been reported as risk factors for placental abruption, and are also risk factors for the development of CP after placental abruption.

In the present study’s multivariate analysis, alcohol consumption was a risk factor for CP after placental abruption. However, alcohol consumption, especially heavy consumption, may be a cause of neurodevelopmental abnormalities, including CP. Smoking was examined separately, before and during pregnancy. The univariate analysis identified smoking before and during pregnancy as risk factors; however, in the multivariate analysis, only smoking during

Figure 2 Forest plots of multivariate analysis. All variables are statistically significant. ● represents aORs. Lines between ● to ● represents 95% CIs.
pregnancy remained significant. This suggests that smoking before pregnancy was tolerable and that smoking cessation during pregnancy could reduce the risk of CP due to placental abruption. This information would be useful for the education of pregnant women. The oral administration of ritodrine hydrochloride was identified as a prepartum risk factor. The reason for this may be that medication is administered outside the hospital setting, where fetal well-being cannot be frequently confirmed, and symptoms may be masked by the medication. Consequently, delayed detection of placental abruption rather than the direct effect of a drug such as ritodrine hydrochloride may be associated with the increased risk of developing CP. Furthermore, in this study, we could not detect a pharmacological effect of ritodrine hydrochloride against the occurrence of placental abruption. Thus, when patients take ritodrine hydrochloride for the management of preterm labor in an outpatient setting, it is important to instruct them on how to respond to changes such as decreased fetal movement, sudden abdominal pain, continuous pain or excessive bleeding, before they start treatment.

Preterm labor showed an cORs of 1.83 in the univariate analysis ($P = 0.002$) but did not remain significant in the multivariate analysis. However, making an accurate differential diagnosis between preterm labor and placental abruption is important because, although their clinical symptoms are very similar, their prognoses are very different. In particular, special attention must be paid to pregnant women on oral ritodrine hydrochloride for preterm labor, who may have already developed placental abruption.

The intravenous administration of oxytocin was identified as a factor that significantly attenuated the risk of developing CP. However, this could be because continuous fetal heart rate tracing led to the early detection of fetal pathological conditions such as a nonreassuring status. The intravenous administration of magnesium sulfate was also identified as a significant factor in the univariate analysis but was not found to significantly attenuate the risk of developing CP in the multivariate analysis. In case of preterm delivery ($\leq 33 + 6$ weeks), administration of magnesium sulfate has been reported as a fetal neuroprotective, and its antenatal use is recommended for neuroprotection of the preterm infant. In this study, intravenous magnesium sulfate was not a significant risk factor, because almost all cases had a gestation period of more than 34 weeks.

Smoking before pregnancy was not a risk factor for placental abruption; however, smoking during pregnancy was a risk factor. This suggests that smoking during pregnancy can reduce the risk of preterm detachment, and it is important to educate women who smoke about this risk.

The present study had some limitations. Since the case and control groups were collected from the different 4-year periods, this may lead to bias related to different practices during different periods. However, during these different periods, critical practices regarding placental abruption were not different. Therefore, collecting data at different periods might have minimal impact. The diagnostic criteria for placental abruption are not uniform. The diagnosis of placental abruption may be biased because it was solely made by the attending physician. It is possible that there was a facility bias because the control cases were extracted from the JSOG-DB. The JSOG-DB is dominated by secondary and tertiary care facilities, while the CP group was dominated by patients from primary care facilities. Thus, the diagnosis of placental abruption may be different between groups with and without CP. As the study did not include infants weighing under 2000 g or cases of fetal death, the risk factors may differ in cases involving more immature fetuses and those with a poor prognosis. Cerebral palsy has a strong link with gestational age. In this study, cases and controls included not only preterm but also term pregnancies. On the other hand, both groups were not different in gestational age distribution. However, to reduce the bias of the gestational age, cases with CP should be matched to the controls with abruption but without CP by gestational age. This issue is one of the significant limitations of this study.

In conclusion, risk factors for the development of CP after placental abruption were identified. Risk factors such as alcohol consumption, smoking during pregnancy and oral administration of ritodrine hydrochloride were included among those that could be ameliorated through educating pregnant women. Medical intervention for preterm labor, especially in the outpatient setting, should be performed appropriately. This includes confirming fetal well-being. The findings suggest the importance of educational activities for pregnant women to increase their awareness of placental abruption and its possible effects.

Acknowledgments
The authors would like to thank Emi Jojima, Yuri Asano, Natsumi Tsuchiya, Hitomi Yuasa, Nozomi Kobayashi, Mio Sano, Sana Ohno, Asami Nagatani,
Miyuki Takeuchi and Saori Ikeda, who are members of the Prevention Recurrence Committee, Japan Obstetric Compensation System for Cerebral Palsy, for their support in data collection and organization. The authors would also like to thank Editage (www.editage.com) for English language editing.

Disclosure
None declared.

Author contributions
Since the content of this paper was discussed and compiled by an organization of 15 people, the number of authors, including co-authors, will be 15.

References
1. Ananth CV, Oyelose Y, Yeo L, Pradhan A, Vintzileos AM. Placental abruption in the United States, 1979 through 2001: Temporal trends and potential determinants. Am J Obstet Gynecol 2005; 192: 191–198.
2. Ananth CV, Smulian JC, Demissie K, Vintzileos AM, Knuppel RA. Placental abruption among singleton and twin births in the United States: Risk factor profiles. Am J Epidemiol 2001; 153: 771–778.
3. Ananth CV, Wilcox AJ. Placental abruption and perinatal mortality in the United States. Am J Epidemiol 2001; 153: 332–337.
4. Hasegawa J, Toyokawa S, Ikenoue T et al. Relevant obstetric factors for cerebral palsy: From the Nationwide Obstetric Compensation System in Japan. PLoS One 2016; 11: e0148122. https://doi.org/10.1371/journal.pone.0148122. eCollection 2016.
5. Shobeiri F, Masoumi SZ, Jenabi E. The association between maternal smoking and placenta abruption: A meta-analysis. J Matern Fetal Neonatal Med 2017; 30: 1963–1967.
6. Yamada T, Yamada T, Morikawa M, Minakami H. Clinical features of abruptio placentae as a prominent cause of cerebral palsy. Early Hum Dev 2012; 88: 861–864.
7. Hayashi M, Nakai A, Satoh S, Matsuda Y. Adverse obstetric and perinatal outcomes of singleton pregnancies may be related to maternal factors associated with infertility rather than the type of assisted reproductive technology procedure used. Fertil Steril 2012; 98: 922–928.
8. Shiozaki A, Matsuda Y, Hayashi K, Satoh S, Saito S. Comparison of risk factors for major obstetric complications between Western countries and Japan: A case-cohort study. J Obstet Gynaecol Res 2011; 37: 1447–1454.
9. Matsuda Y, Hayashi K, Shiozaki A, Kawamichi Y, Satoh S, Saito S. Comparison of risk factors for placental abruption and placenta previa: Case-cohort study. J Obstet Gynaecol Res 2011; 37: 538–546.
10. Tommaso MD, Tranquilli A. A checklist to identify the origin of cerebral palsy. J Matern Fetal Neonatal Med 2004; 15: 281–286.
11. Finischi V, Viola RV, Russa RL, Santurro A, Frati P. A controversial Medicolegal issue: Timing the onset of perinatal hypoxic-ischemic brain injury. Mediat Inflamm 2017; 2017: 6024959. https://doi.org/10.1155/2017/6024959. Epub 2017 Aug 13.
12. The Japan Obstetric Compensation System for Cerebral Palsy. Looking back over 10 years after System was launched. 2017. Available from URL: http://www.sanka-hp.jcqhc.or.jp/documents/english/pdf/looking_back_over_10years_after_system_was_launched201906.pdf
13. McIntyre S, Taitz D, Keogh J, Goldsmith S, Badawi N, Blair E. A systematic review of risk factors for cerebral palsy in children born at term in developed countries. Dev Med Child Neurol 2013; 55: 499–508.
14. Matsuda Y, Umezaki H, Ogawa M, Ohwada M, Satoh S, Nakai A. Umbilical arterial pH in patients with cerebral palsy. Early Hum Dev 2014; 90: 131–135.
15. Prevention Recurrence Committee, Japan Obstetric Compensation System for Cerebral Palsy in Public Interest Incorporated Foundation, Japan Council for Quality Health Care, 6th Recurrence Prevention Report (Japanese). 2016. Available from URL: http://www.sankahp.jcqhc.or.jp/documents/prevention/report/pdf/Saihatsu_Report_06_All.pdf
16. MacLennan A. A template for defining a causal relationship between acute intrapartum events and cerebral palsy: International consensus statement. Aust N Z Obstet Gynaecol 2000; 40: 13–21.
17. Freeman RK. Medical and legal implications for necessary requirements to diagnose damaging hypoxic-ischemic encephalopathy leading to later cerebral palsy. Am J Obstet Gynecol 2008; 199: 585–586.
18. Matsuda Y, Ogawa M, Kono J, Mitani M, Matsui H. Prediction of fetal acidaemia in placental abruption. BMC Pregnancy Childbirth 2013; 13: 156.
19. O’Leary CM, Watson L, D’Antoine H, Stanley F, Bower C. Heavy maternal alcohol consumption and cerebral palsy in the offspring. Dev Med Child Neurol 2012; 54: 224–230.
20. Magee LA, De Silva DA, Sawchuck D, Synnnes A, von Dadelszen P. No. 376-magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can 2019; 41: 505–522.